A peripherally restricted cannabinoid-1 receptor inverse agonist promotes insulin secretion and protects from cytokine toxicity in human pancreatic islets-Reference-Cited by-同舟云学术

A peripherally restricted cannabinoid-1 receptor inverse agonist promotes insulin secretion and protects from cytokine toxicity in human pancreatic islets

Published:2023-04 Issue: Volume:944 Page:175589
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Ghosh Anindya^ORCID,Peyot Marie-Line,Leung Yat Hei,Ravenelle François,Madiraju S R Murthy,Prentki Marc

Funder

Mitacs

Publisher

Elsevier BV

Subject

Pharmacology

Reference39 articles.

1. 'A pharmacological primer of biased agonism;Andresen;Endocr., Metab. Immune Disord.: Drug Targets,2011

2. 'C3aR and C5aR1 act as key regulators of human and mouse beta-cell function;Atanes;Cell. Mol. Life Sci.,2018

3. 'CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity;Baillie;Mol. Pharmacol.,2013

4. 'Very-Long-Chain unsaturated sphingolipids mediate oleate-induced rat beta-cell proliferation;Castell;Diabetes,2022

5. 'Lisofylline, a novel antiinflammatory agent, protects pancreatic beta-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism;Chen;Endocrinology,2002

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans;Diabetologia;2024-06-12

2. Effects of CB1R inverse agonist, INV‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study;Diabetes, Obesity and Metabolism;2023-11-08